Supplementary Fig. S1. Calfacilitin is conserved among different species.

Calfacilitin Human Chimpanzee Mouse Zebrafish	MGPGWRAPSAALVGGSVALFGALRRAALALPRPAAVRSRPGRVWRWRNLLVSFAHSV MPRLLHPALPLLLGATLTFRALRRALCRLPLPVHVRADPLRTWRWHNLLVSFAHSI MPRLLHPALPLLLGATLTFRALRRALCRLPLPVHVRADPLRTWRWHNLLVSFAHSI MDTWLNEVQKFPVLYVLCCSVLFRILHWCLQIVARPDTVTKDRWKTWKWRNLSVSLVHSL . : . * *: :. * * :.:*:*:**
Calfacilitin Human Chimpanzee Mouse Zebrafish	LAGLWALFSLWQSPELLSDIQDGYSVSGHLLVCFSSGYFIHDSLDIIFNQQSRSSWEYLV VSGIWALLCVWQTPDMLVEIETAWSLSGYLLVCFSAGYFIHDTVDIVASGQTRASWEYLV VSGIWALLCVWQTPDMLVEIETAWSLSGYLLVCFSAGYFIHDTVDIVTSGQTRASWEYLV VSGIWALLCLWQTPEMLVEIETAWSASGYLLVCFSAGYFIHDTVDIVVSKQTRASWEYLV LTGTWAVACVIYYPAMVHEIHSTYTPSAYMLVVVSSGYFIEDAADIVFSGHAKASWEFLL ::* **: : * :: : * :: : *:::** .*:******
Calfacilitin Human Chimpanzee Mouse Zebrafish	HHAMAISAFVSLIITGRFLVAAMLLLLVEVSNIFLTIRMLLKMS-NVPSPALYEANKYVN HHVMAMGAFFSGIFWSSFVGGGVLTLLVEVSNIFLTIRMMMKIS-NAQDHLLYRVNKYVN HHVMAMGAFFSGIFWSSFVGGGVLTLLVEVSNIFLTIRMMMKIS-NAQDHLLYRVNKYVN HHVMAMGAFFSGIFWKRFVGGGVLTLLVEVSNIFLTLRMMMKIN-NAQDLLLYKVNKYIN HHVLVLWCFLYAVFTHQYVAGAVVALFVEVNSVFLHTRLLLNLAKVAHSSLIYTVNKVLN **: .*. :: :: :: :: *: *: *: *: *: *: *: *: *:
Calfacilitin Human Chimpanzee Mouse Zebrafish	LVMYFAFRLAPQVYLTWYFVRYVEVQGQGAFLMANLLLLDAMILMYFSRLLRSDFFPSLR LVMYFLFRLAPQAYLTHFFLRYVNQRTLGTFLLGILLMLDVMIIIYFSRLLRSDFCP LVMYFLFRLAPQAYLTHFFLRYVNQRTLGTFLLGILLMLDVMIIIYFSRLLRSDFCP LVMYFLFRLAPQAYLTKFFLQYAGQRTLGTFLLAILLMLDLMIIIYFSRLLRSDFCP VVTYVTFRLGAQFYLTWYLTYHYSSLDYALYFLITTMLMNIMILIYFYRLIRSDFFTKRR :* *. **** *** :: : ::: :::: **::** **:****.
Calfacilitin Human Chimpanzee Mouse Zebrafish	KGSVGRDVDGEKFLID -EHVPKKQHKDKFLTE -EHVPKKQHKDKFLTE -ERAPRRQQKDKFLTE IQNGIQKLAAD : :

Sequence alignment of the predicted protein sequence of Calfacilitin with its putative orthologues in other species. Chick Calfacilitin has been submitted to GenBank and assigned accession number GQ504719. Orthologues: Zebrafish: AAH83250.1; Mouse: NP_080984; Chimpanzee: XP_511362.1; Human: BC014072.1. Shaded areas correspond to the predicted transmembrane domains, which are conserved.

Supplementary Fig. S2. Lack of effect of calfacilitin on Ca_v1.3 channels.



a. Normalized *I*-V curved for I_{Ca} . $V_{0.5}$ (Ca_V1.3) = -19.36±0.64 mV (n=7). $V_{0.5}$ (Ca_V1.3-Calfacilitin) = -20.0±0.53 mV (n=5). P>0.05 (Student's *t*-test). **b.** Steady-state inactivation properties. $V_{0.5}$ (Ca_V1.3) = -46.3±0.64 mV (n=7). $V_{0.5}$ (Ca_V1.3-Calfacilitin) = -45.9±0.3 mV (n=7). P>0.05 (Student's *t*-test). **c.** Representative I_{Ba} during depolarizations to V_{max} and percentage of I_{Ba} inactivation. No difference was found between the presence and absence of calfacilitin. $N_{cell}=7$ (Ca_V1.3). $N_{cell}=5$ (Ca_V1.3-Calfacilitin). **d.** Representative I_{Ca} and percentage I_{Ca} inactivation during depolarizations to -10, 0 and 10 mV at 0.1 and 0.3 s after peak current. There is no difference between the presence and absence of calfacilitin). Error bars in all panels correspond to the standard error of the mean.

Supplementary Fig. S3. Nicardipine treatment does not affect expression of *Chordin*.



Embryo treated with Nicardipine as shown in Fig. 5c, after in situ hybridisation with the organizer marker *Chordin*. This embryo is at stage 4^+ and expression is confined, as in normal embryos, to the organizer and emerging head process (dark blue signal). Scale bar: 100 μ m.

Supplementary Fig. S4. Morpholino directed against an exon-intron junction of Calfacilitin causes exon-skipping and generates a truncated form.



Embryos were electroporated with Control (Co-MO, Lanes 2-3) or Calfacilitin (CaFac-MO, Lanes 4-5) morpholinos, the latter targeting a splice junction. The products were amplified by RT-PCR. Lane 1, size markers (Promega 1kb ladder; the lowest four markers correspond to 253, 500, 750 and 1000 bp respectively, from bottom to top). Lanes 3 and 5 contain the same samples as 2 and 3 but Reverse Transcriptase (RT) was omitted as a control. Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) was used as a loading control. The Morpholino causes a decrease in the Calfacilitin (CaFac) band and appearance of a smaller band corresponding to a truncated version caused by exon skipping (arrowhead). Note that electroporation targets a mosaic of cells therefore each sample is a mixture of targeted and normal cells; this can account for the remaining full-length Calfacilitin in the CaFac-MO sample.